글로벌 골다공증 약물 시장 – 2030년까지의 산업 동향 및 예측

골다공증 치료제 시장 분석 및 규모

글로벌 골다공증 약물 시장은 노령 인구 증가, 골다공증 유병률 증가, 뼈 건강에 대한 인식 증가와 같은 요인에 의해 꾸준한 성장을 경험하고 있습니다. Data Bridge Market Research는 2022년에 15,576.30백만 달러였던 골다공증 약물 시장이 2030년까지 20,332.57백만 달러로 급증할 것이며 예측 기간 동안 4.68%의 CAGR을 경험할 것으로 분석했습니다. 이는 시장 가치를 나타냅니다. 전 세계적으로 골다공증 유병률이 증가함에 따라 약물 치료에 대한 수요가 증가함에 따라 "약물"이 골다공증 약물 시장의 치료 유형 부문을 지배하고 있습니다. 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

골다공증 약물 시장 범위 및 세분화

시장 정의

골다공증은 뼈가 약해지거나 뼈가 약해져 부러지기 쉬운 상태입니다. 즉, 골다공증은 뼈 밀도가 감소하는 상태입니다. 이는 특히 노년층에서 나타납니다. 골다공증은 허리 통증, 구부정한 자세, 뼈 골절 및 치아 상실을 초래합니다.

골다공증 약물 시장 동향

운전자

• 골다공증 유병률 증가

골다공증의 유병률은 주로 생활 방식의 변화, 열악한 식단 및 앉아서 지내는 생활 방식으로 인해 전 세계적으로 증가하고 있습니다. 골다공증에 기여하는 요인으로는 신체 활동 감소, 칼슘 과 비타민 D 섭취 부족 , 호르몬 불균형 등이 있습니다. 골다공증을 앓고 있는 사람의 수가 증가함에 따라 골다공증 약물에 대한 수요가 크게 증가하고 있습니다.

• 인지 및 진단 증가

골다공증과 그 결과에 대한 인식은 의료 전문가와 일반 대중 모두에서 상당히 증가했습니다. 건강 기관, 환자 옹호 단체 및 제약 회사의 이니셔티브는 사람들에게 골다공증 예방, 조기 발견 및 사용 가능한 치료 옵션에 대한 교육을 제공하는 데 중요한 역할을 했습니다. 결과적으로 점점 더 많은 사람들이 골다공증 진단을 받고 골다공증 약물에 대한 수요가 증가하고 있습니다.

• 약물 개발의 기술적 진보

약물 개발의 기술적 진보로 골다공증에 대한 보다 효과적이고 표적화된 치료법을 발견하고 개발할 수 있게 되었습니다. 첨단 영상 기술, 분자 생물학 및 유전체학을 사용하여 골다공증의 병태생리에 대한 통찰력을 제공하고 새로운 약물 표적을 식별하게 되었습니다. 새로운 약물 전달 시스템과 제형 기술의 개발은 또한 골다공증 약물의 효능과 환자 준수도를 개선할 것입니다. 

• 의료 시설에 대한 투자 증가

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities

Opportunities

• Targeted Therapies and Personalized Medicine

The development of targeted therapies and personalized treatment approaches offers the opportunity to improve the effectiveness and safety of osteoporosis treatment. Advances in genomics, biomarker identification and precision medicine enable specific patient subgroups that may benefit from tailored treatment. By developing innovative treatment methods that meet the individual characteristics and needs of the patient, treatment results can be improved and products can be differentiated in the market 

• Research and Development for New Drug Candidates

Ongoing research and development in the field of osteoporosis offers opportunities for the discovery and development of new drug candidates. Exploring new mechanisms of action, identifying innovative drug targets and exploiting advances in drug delivery systems can lead to the development of innovative therapies with greater efficacy and fewer side effects. Companies that invest in RandD to expand their product portfolio can take advantage of these opportunities and gain a competitive advantage in the market 

Restraints

• Patent Expiration and Generic Competition

Many osteoporosis drugs have had patent expirations, allowing generic versions to enter the market. Generic drug competition often leads to lower prices, which reduces the revenue potential of originator drug manufacturers. This may affect profitability and hinder the growth of the osteoporosis drug market 

• Side Effects and Safety Concerns

Osteoporosis medications, such as all medications, can have potential side effects and safety concerns. Some medications have been associated with rare but serious side effects, such as atypical fractures and osteonecrosis of the jaw. These safety concerns may lead to regulatory actions, warnings, and restrictions affecting the prescribing and marketing of certain osteoporosis drugs

Challenges

• High Development Costs and Long Development Times

Developing and marketing a new osteoporosis drug requires significant research and development costs, including preclinical studies, clinical trials and regulatory notifications. The process can be time-consuming and often takes years from initial discovery to commercialization. In addition, the high failure rate of clinical trials further increases costs and lengthens development schedules. These challenges increase the financial burden on pharmaceutical companies and create uncertainty about the return on invested capital 

• Reimbursement and Pricing Pressures

Osteoporosis drugs, especially the newer biologics, can be expensive. Pricing pressures from health systems, payers and insurance companies can limit the availability and affordability of these drugs. Reimbursement policies, formulary restrictions, and cost containment measures can affect market access, patient affordability, and overall market demand. Pharmaceutical companies must overcome these challenges to secure favourable reimbursement and pricing agreements while demonstrating the value and cost-effectiveness of their products 

This osteoporosis drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Osteoporosis Drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Recent Developments

• In August 2021, Enzene Biosciences Ltd received Marketing Authorization (MA) from the Drug Controller General of India (DCGI) for its biosimilar drug, denosumab, indicated for the treatment of osteoporosis in adults
• In January 2021, Theramex, a London-headquartered pharmaceutical company, launched the osteoporosis medicine Livogiva in Europe

Global Osteoporosis Drug Market Scope

The osteoporosis drug market is segmented on the basis of type, therapy type, treatment type, mechanism of action, route of administration and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Primary osteoporosis
• Postmenopausal osteoporosis
• Senile osteoporosis
• Idiopathic osteoporosis
• Seocndary osteoporosis

Therapy type

• Hormone Replacement Therapy​​​​​​​
• Testosterone Replacement Therapy
• Estrogen Therapy
• Bisphosphonate Therapy

Treatment type

• Medication
• Calcium
• Vitamin D Supplements
• Antacids
• Surgery
• Vertebroplasty
• Kyphoplasty
• Others

Mechanism of Action

• Bisphosphonates
• Alendronate
• Ibandronate
• Risedronate
• Zoledronic
• Selective Estrogen Receptor Modulators
• Raloxifene
• Bone Resorption Inhibitors
• Denosumab

Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Others

End-User

• Hospitals
• Homecare
• Specialty clinics
• Others

Osteoporosis Drug Market Regional Analysis/Insights

The osteoporosis drug market is analysed and market size insights and trends are provided by country, type, therapy type, treatment type, mechanism of action, route of administration and end-users as referenced above.

The countries covered in the osteoporosis drug market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the osteoporosis drug market owing to the easy availability of osteoporosis drugs and rising prevalence of osteoporosis.   

Asia-Pacific is projected to score highest growth rate for the forecast period owing to rising expenditure to develop healthcare infrastructure coupled with growth and expansion of life sciences industry.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The Osteoporosis drug market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Osteoporosis drug market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Osteoporosis Drug market. The data is available for historic period from 2021 to 2030.

Competitive Landscape and Osteoporosis Drug Market Share Analysis

The osteoporosis drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to osteoporosis drug market.

Some of the major players operating in the osteoporosis drug market are

• GlaxoSmithKline plc. (U.K.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Eli Lilly And Company. (U.S.)
• Astrazeneca (U.K.)
• Pfizer Inc. (U.S.)
• Takeda Pharmaceutical Company Limited. (Japan)
• 브리스톨-마이어스 스퀴브 회사(미국)
• 사노피(프랑스)
• 존슨앤존슨서비스(주)(미국)
• Bayer AG(독일)
• AbbVie Inc.(미국)
• 알러간(아일랜드)
• 머크앤코(미국)
• 암젠 주식회사(미국)
• Sun Pharmaceutical Industries Ltd. (인도)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• Novo Nordisk A/S(덴마크)
• 다이이치 산쿄 주식회사(일본), 유한회사.
• Cipla Inc. (인도)

SKU-42545